NEW YORK (GenomeWeb) – Paradigm and Forma Therapeutics today announced a multiyear partnership to identify predictive response biomarkers and measure pharmacodynamic activity for two of Forma's advanced preclinical candidates.
Paradigm will use its technology to evaluate the potential of molecular markers to predict clinical outcomes, which would enable Forma "to efficiently match our drugs with high-quality molecular assays to realize a personalized approach to cancer drug development," Forma President and CEO Steven Tregay said in a statement.
Through a spokesman, Forma declined to disclose the target and disease indications for the two therapeutic candidates. He added that certain details of the agreement are being finalized, but that for some projects Paradigm's PCDx test will be used, while for others, different assays could be developed.
PCDx is a next-generation sequencing-based cancer test that sequences both DNA and RNA.
Forma will also "be leveraging [Paradigm's] evidence team and biomarker expertise to develop target strategies," the spokesman said. Financial and other terms of the deal were not disclosed.
Last week Paradigm announced it initiated genomic testing for Pharmatech's AccessPPM Cancer Registry.